Giant cell arteritis management has undergone a significant paradigm shift. Giant cell arteritis (GCA) stands as the most frequent systemic vasculitis in adults over 50 years. Specifically, clinicians must remain vigilant regarding aortic involvement, which often remains clinically silent. This complication increases the risk of thoracic aortic aneurysms. Consequently, experts emphasize early detection through structured imaging to improve long-term vascular outcomes.

Advancements in Giant Cell Arteritis Management and Aortitis Care

Historically, glucocorticoids served as the primary treatment for GCA. However, their prolonged use frequently leads to severe adverse effects. Modern strategies now advocate for a treat-to-target approach. This methodology aims for both clinical and imaging remission. In addition, research highlights the critical roles of Th17 and Th1 immune pathways in driving vessel wall inflammation. Targeted therapies, particularly tocilizumab, have revolutionized the standard of care by acting as potent steroid-sparing agents. Furthermore, Janus kinase (JAK) inhibitors like upadacitinib show promising results in maintaining sustained remission.

Imaging plays a central role in contemporary diagnosis and monitoring. According to recent guidelines, ultrasound of the temporal and axillary arteries remains the preferred first-line test. Alternatively, physicians may use FDG-PET or MRI to detect mural inflammation in extracranial vessels. These modalities allow for the objective assessment of disease activity. Moreover, they help identify subclinical aortitis before irreversible structural damage occurs. Therefore, early intervention with emerging biotherapies significantly enhances the prognosis for patients with large-vessel involvement.

Frequently Asked Questions

How does subclinical aortitis impact the prognosis of GCA?

Subclinical aortitis significantly increases the risk of developing thoracic aortic aneurysms and dissections later in life. Regular monitoring through imaging helps identify early vascular changes, allowing for more aggressive therapeutic intervention to prevent structural damage.

What is the benefit of using tocilizumab in giant cell arteritis management?

Tocilizumab specifically targets the interleukin-6 (IL-6) pathway, which is a major driver of inflammation in GCA. By using this biologic agent, clinicians can achieve higher rates of sustained remission while significantly reducing the patient's cumulative glucocorticoid exposure and related toxicity.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Secada-Gómez C et al. Advances in the management of giant cell arteritis-aortitis: biologic therapies and beyond - a narrative review. Expert Opin Biol Ther. 2026 Mar 23. doi: 10.1080/14712598.2026.2650104. PMID: 41872075.

Dejaco C, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update. Ann Rheum Dis. 2024;83(6):741-751.

Stone JH, et al. Upadacitinib for the treatment of giant cell arteritis: a phase 3, randomized, double-blind, placebo-controlled trial. Lancet. 2024;403(10438):1741-1751.